Esperion Therapeutics (ESPR) has signed a settlement agreement with a fifth generic drug applicant.

According to the terms of the agreement, the generic drug applicant is prohibited from marketing generic versions of Nexletol® (bempedoic acid) and Nexlizet® (bempedoic acid/ezetimibe) before April 19, 2040. The conclusion of this agreement further consolidates the market exclusivity period for Esperion's core product portfolio. Nexletol and Nexlizet are important products for the company in the treatment of hypercholesterolemia, and the extension of their market exclusivity has a positive impact on the company's future revenue prospects.